Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Rating) – Equities research analysts at Litchfield Hills Research upped their Q2 2023 earnings per share estimates for Adial Pharmaceuticals in a report released on Thursday, May 18th. Litchfield Hills Research analyst T. O’neill now expects that the company will post earnings of ($0.09) per share for the quarter, […]